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DEVELOPING A PREDICTIVE MORTALITY RISK ALGORITHM FOR 
PRETERM NEONATES REQURING SURGICAL INTERVENTION AT 
BOSTON CHILDREN’S HOSPITAL 
MICHAEL ROMANO 
ABSTRACT 
 
Introduction: Preterm infants have high mortality rates worldwide (Blencowe et al., 
2013). The leading causes of infant mortality in the United States are preterm birth, low 
birth weight, and birth defects (Ely, Driscoll, & Matthews, 2018). The aim of this study is 
to compare demographics and patient characteristics between surviving and deceased 
neonates who had fewer than 39 weeks of gestation and required surgical intervention at 
Boston Children’s Hospital (BCH), and to report clinical characteristics among the 
deceased population. By identifying significant prognostic factors of mortality in this 
patient population, a future predictive mortality risk algorithm can be developed. 
 
Methods: After IRB approval, data was obtained from electronic medical records. All 
patients born before 39 weeks of gestation from 2013-2018 and had a surgical procedure 
at BCH within the first thirty days of life were included. Demographic characteristics 
were compared between survivors and deceased patients, and clinical variables are 
presented among deceased neonates. Statistical testing was done by the Wilcoxon rank 
sum test and Fisher’s exact test. 
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Results: 653 patients were included in the dataset, 56 of whom were deceased, an 8.6% 
mortality rate. The median gestational age of the deceased and surviving patients was not 
statistically different, 35 weeks and 36 weeks respectively (p=0.076). In addition, there 
was no significant difference between the ratio of males to females between the two 
groups (p=0.234). However, mortality rates were significantly different across gestational 
age categories (p=0.015) between deceased and surviving patients. In addition, lower 
birth weight (p=0.009) and higher ASA classification (an anesthesia preoperative 
physiological assessment score) (p<0.001) were both independently associated with 
significantly higher mortality rates. Due to time constraints, only a descriptive analysis 
could be done on certain clinical variables among the deceased population. Among the 
deceased group, 62.5% of the surgical procedures were cardiac-related. The median 
maximum intraoperative lactate value for the entire deceased population was 6.5 mmol/L 
(IQR: 4.3–8.7). The median age at death was 46 days (IQR: 25-109), and 58.9% of all 
deceased patients had their care redirected to comfort measures only. Nearly half of the 
deceased population (27/56; 48.2%) had at least one CPR (cardiopulmonary 
resuscitation) event. Future analysis will compare these factors against the surviving 
patients to determine if a significant association with mortality exists. 
 
Discussion: The mortality of preterm infants occurs at a high rate. While there were no 
significant differences between the deceased and surviving groups in terms of gender 
distribution or gestational age, lower birth weight and higher ASA classification were 
both independently associated with significantly higher mortality rates; this suggests that 
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the deceased patients were smaller and had more complex medical histories than the 
surviving group. The majority of deceased patients underwent cardiac-related procedures 
and most had CPR performed at least once. Further investigation of the entire study 
population is necessary. A better understanding of the factors that contribute to preterm 
infant mortality could help families and health professionals to make complex decisions 
about medical interventions.  
 
Conclusion: Additional analysis is needed to further identify and better understand 
patterns in premature neonate mortality at Boston Children’s Hospital.  
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INTRODUCTION 
 
Infant and Neonatal Mortality 
 The neonatal period, defined as the first 28 days of life, is an extremely vulnerable 
time period corresponding to the highest risk of infant mortality (UNICEF, WHO, World 
Bank Group, & United Nations, 2018). Globally, the neonatal mortality rate was 18 
deaths per 1000 births, with approximately 2.5 million neonatal deaths in 2017 alone 
(“Neonatal mortality,” 2018). Of the 2.5 million neonatal deaths that occurred, roughly 1 
million deaths were on the first day of life, and a subsequent 1 million deaths occurred 
within the next six days (“Neonatal mortality,” 2018). While neonatal mortality is very 
high, there have been significant reductions in neonatal mortality over the last thirty 
years. In 1990 the global neonatal mortality rate was 37 deaths per 1000 births with 5 
million neonatal deaths that year (UNICEF et al., 2018). From 1990 to 2017, the global 
neonatal mortality rate and total number of neonatal deaths have both decreased by 
approximately 50%.   
 Total infant mortality is usually broken down into neonatal (age 0-28 days) and 
post-neonatal (age 29-364 days) periods (Ely et al., 2018). Data from the United States in 
2017 indicate that the neonatal and post-neonatal mortality rates were 3.88 and 1.99 
deaths per 1000 births respectively, corresponding to a total infant mortality rate of 5.87 
per thousand births (Ely et al., 2018). Comparison of the neonatal mortality rate with the 
total infant mortality rate reveals that neonates made up two-thirds of all infant deaths in 
the United States (Table 1). While the United States has seen a ten percent decline in 
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neonatal mortality from 2007 to 2011, there have not been significant changes in either 
neonatal or post-neonatal mortality rates from 2011 to 2016 (Ely et al., 2018).  
 
Table 1. Comparisons of Global Neonatal Mortality and Infant Mortality in 2017. 
Table amended from UNICEF et al., 2018 
 
Region Infant Mortality 
Rate (deaths per 
1000 births) 
Neonatal Mortality 
Rate (deaths per 
1000 births) 
Neonatal 
proportion of Infant 
deaths (%) 
Africa 51 27 53% 
Europe 8 5 63% 
South-East Asia 29 21 72% 
United States 6 4 66% 
Global 29 18 62% 
 
 Just as the neonatal and post-neonatal mortality rates are significantly different, so 
too are the leading causes of death for each respective group. For neonates in the United 
States, the top three causes of death in 2016 were low birth weight, congenital 
malformations, and maternal complications (Ely et al., 2018). For post-neonatal infants 
the top three causes of death in 2016 were congenital malformations, sudden infant death 
syndrome, and unintentional injuries (Ely et al., 2018). When we look at risk factors 
associated with neonatal mortality, we find that prematurity is associated with over 50% 
of all neonatal deaths (Blencowe et al., 2013). In 2010, one million neonatal deaths were 
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the direct result of prematurity and another 800,000 deaths were the indirect result of 
preterm birth, with or without intrauterine growth restriction, resulting from 
complications such as infection (Howson, Kinney, McDougall, & Lawn, 2013).The 
impact of prematurity as a serious risk factor in neonatal health is also not confined to 
developing countries. In almost all middle and high-income countries in the world, the 
direct and indirect consequences of preterm birth are the leading cause of neonatal death 
(Blencowe et al., 2013).  
 
Prematurity 
 The World Health Organization (WHO) defines preterm or premature birth as 
being born alive before completing 37 weeks of gestation (“Preterm birth,” 2018). 
Globally, it is estimated that 41,000 infants are born preterm each day (Platt, 2014). 
While more specific estimates of the extent and prevalence of preterm birth has been 
difficult to assess across the world, estimates by the WHO in recent years have shed new 
light on prematurity’s pervasive effects (Howson et al., 2013). In the landmark report, 
Born too Soon: The Global Action Report on Preterm Birth, WHO et al. showed for the 
first time the country-specific estimates of prematurity with reliable trend data showing 
that rates of prematurity are increasing worldwide (World Health Organization, March of 
Dimes, The Partnership for Maternal, Newborn & Child Health, & Save the Children, 
2012). While the global preterm birth rate was estimated to be 11.1% in 2010, there are 
significant variations in this rate depending on the geographic region and country 
(Blencowe et al., 2013). The areas of Southern Asia and Sub-Saharan Africa have the 
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highest preterm birth rate (12.8%), making up 60% of all global preterm births 
(Blencowe et al., 2013). While not as high, the United States, in comparison, had a 12.0% 
preterm birth rate in 2010 and accounted for 42% of all preterm births in developed 
countries (Blencowe et al., 2012). Estimates for preterm birth show a consistent increase 
in the preterm birth rate over time. Trends of preterm birth from 1990 to 2010 show a 
consistent increase in the number of preterm births per year, with an estimated 19.4% 
increase in developed countries over that time (Blencowe et al., 2012). In the United 
States however, there has been a slight decline in recent years. Reaching as high as 12.8% 
in 2006, the preterm birth rate in the United States as of 2015 has gone down to 9.62% 
(Purisch & Gyamfi-Bannerman, 2017). 
In developing countries human viability, defined as the gestational age at which 
the chance of survival is 50%, is 23-24 weeks (Glass et al., 2015). To better categorize 
preterm patients, prematurity has been classified by the extent of gestation before birth: 
extremely preterm (<28 weeks’ gestation), very preterm (28 weeks to 31 weeks 6/7 days), 
moderately preterm (32 weeks to 33 weeks 6/7 days), and late preterm (34 weeks to 36 
weeks 6/7 days) (Schonhaut, Armijo, & Pérez, 2015).1 While this 37 week cutoff 
formally defines prematurity, it is known that babies born at 38 and 39 weeks’ gestation 
still have higher mortality and morbidity risks than babies born at 40 weeks (Blencowe et 
al., 2013). In the United States, the majority of preterm births are in the late preterm 
																																																								1	The	written	notation	for	gestational	age	was	used	based	on	past	studies	and	is	consistent	with	current	literature	(e.g.	31	weeks	6/7	days	refers	to	31	weeks	and	6	days	old).	
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period, and represent 71.4% of all preterm births (Table 2) (Purisch & Gyamfi-
Bannerman, 2017). 
 
Table 2. Prevalence of Preterm Birth by Gestational Age in the United States; 2015. 
Table amended from Purisch & Gyamfi-Bannerman, 2017 
 
Gestational Age 
Category 
Number of Weeks % of all Preterm 
Births 
% of all Births 
Late Preterm 34 to 36 6/7 weeks 71.4% 6.87% 
Moderate 
Preterm 
32 to 33 6/7 weeks 12.2% 1.17% 
Early Preterm <32 weeks 16.4% 1.58% 
 
 The types of premature birth broadly fall into two sub-types: spontaneous preterm 
birth and provider-initiated preterm birth (Blencowe et al., 2013). Sometimes referred to 
as an iatrogenic preterm birth, the use of obstetric intervention commonly occurs when 
the risk of continuing the pregnancy is greater than the risks, to either mother or child,  of 
preterm birth  (Platt, 2014). Some common conditions that require immediate delivery 
regardless of gestational age include: acute fatty liver of pregnancy, chorioamnionitis, 
and eclampsia (Chescheir & Menard, 2012). Furthermore, Chescheir et al. evaluated 
various “soft” risk factors that may result in iatrogenic preterm birth between 34 and 38 
weeks and found several associated conditions such as oligohydramnios, small fetus for 
gestational age, well-controlled gestational diabetes, prior uterine scaring, and pregnancy 
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associated hypertension. While the American College of Obstetrics and Gynecology has 
recommended against elective iatrogenic birth before 39 weeks, a large multicenter study 
found that over one-third of all elective cesarean births were done before this 39 week 
recommendation (Chescheir & Menard, 2012). While this is more common in developed 
countries, it is not as prevalent in developing nations such as Africa where the rates of 
cesarean sections are less than 5% (Blencowe et al., 2012). Spontaneous preterm birth 
can be further subdivided into two subtypes: preterm premature rupture of the membranes 
(PPROM) and spontaneous preterm birth with intact membranes (Goldenberg, Culhane, 
Iams, & Romero, 2008). 
 
Risk Factors of Preterm Pregnancy 
While the specific etiology of preterm birth remains relatively unknown, there are 
several identifiable risk factors that increase the odds of preterm birth: prior spontaneous 
preterm birth, short cervix, non-Hispanic, black race, multiple gestations, and uterine 
anomalies (Purisch & Gyamfi-Bannerman, 2017). Additional risk factors mentioned by 
Räisänen et al include: advanced maternal age, smoking, obesity, genital infections, 
primiparity, and assisted reproductive technology (Räisänen, Gissler, Saari, Kramer, & 
Heinonen, 2013). 
Because many of the etiologic risks of preterm birth are associated with systemic 
and/or pathologic inflammation, recent studies have looked at genetic variants of genes 
associated with inflammatory response in both genome-wide association assays and 
whole exome sequencing (Strauss et al., 2018). Oros et al observed distinctly different 
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gene expression patterns that were indicative of inflammation in the placentas of 
suspected preterm patients. They showed a positive correlation between preterm birth and 
gene expression of known cytokine inflammatory markers interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNFα) based on placental and umbilical cord blood samples (Oros 
et al., 2017). Furthermore, recent studies by Zhang et al have shown three specific loci 
(EBF1, EEFSEC, and AGTR2) to be associated with preterm birth and gestational 
duration in a large scale genome association assay of European mothers (Zhang et al., 
2017).    
While there have been many strides in the advancement of neonatal care to 
improve health outcomes, there still exist health disparities and known mortality risk 
differences depending on factors such as race and ethnicity. As stated previously, non-
Hispanic black mothers have a higher risk of spontaneous preterm birth. In fact, data 
from 2012 to 2014 in the United States showed preterm birth rates of non-Hispanic Black 
women to be 48% higher compared to those of other racial groups (Purisch & Gyamfi-
Bannerman, 2017). Several studies comparing preterm birth rates by race/ethnicity have 
shown disparities even when researchers controlled for confounders such as 
socioeconomic factors (Purisch & Gyamfi-Bannerman, 2017). Looking at this further, 
Manuck et al. concluded that these disparities for non-Hispanic Black women were not 
the result of one specific factor, but rather a more complex multifactorial relationship 
between several factors including maternal education, differences in biomarkers, genetic 
variation, and differing microbiomes of non-Hispanic black women as compared to non-
Hispanic white women (Manuck, 2017). 
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Several studies have looked at possible genetic, epigenetic, or biomarkers 
associated with these preterm birth disparities in non-Hispanic Black women. In a review 
by Purisch et al, several groups found that the TNF-2 allele of the TNFα gene was 
associated with higher spontaneous preterm birth in non-Hispanic black women as 
compared to non-Hispanic white women (Purisch & Gyamfi-Bannerman, 2017). 
Additional research has shown racial differences in DNA methylation, leading to further 
investigation into the effects of epigenetics. In one such study, Salihu et al looked at 42 
CpG sites on 20 genes consistently reported in the literature to be associated with preterm 
birth. Their results showed that three CpG sites on the TNFAIP8 and PON1 genes had 
significantly different rates of methylation in non-Hispanic black versus non-Hispanic 
white individuals (Salihu et al., 2016). 
 
Preterm Mortality and Morbidity 
 Several studies have previously shown an increase in mortality as gestational age 
at birth decreases. While many of these studies used older data from smaller cohorts, a 
recent population-based analysis by Manuck et al. has provided an updated analysis of 
preterm outcomes (Manuck et al., 2016). The aforementioned study looked at data from 
25 hospitals in 2008-2011 that included a cohort of 115,502 pregnant women, of which 
8334 deliveries met inclusion criteria. Their results showed a total neonatal mortality rate 
of 1.4%, or 199 neonatal deaths in 8334 births, and a rapid decline in mortality rate with 
each increasing week of gestation (Figure 1).  
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Figure 1: Preterm mortality rate by gestational age of neonates born in the United 
States. Figure based on data from Manuck et al., 2016 
 
 While preterm prognostic assessment is largely driven by gestational age at birth, 
many other factors may contribute to preterm neonatal mortality such as birth weight and 
sex (Delorme et al., 2016). Examining a cohort of over 1.5 million births in the province 
of Ontario, Canada, Ray et al. analyzed the combined effects of severe small for 
gestational age (SGA) births (<5% percentile) and preterm births to see how mortality 
rates differed (Ray, Park, & Fell, 2017). Their results showed a significantly higher 
mortality rate for patients born 23-28 weeks with severe SGA as compared to those 
without severe SGA, in addition to higher mortality rates in males versus females, even 
after accounting for possible confounding demographic factors (Ray et al., 2017).  
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Additionality, several studies have looked at how neonatal mortality rates differ 
depending on the specific cause of preterm birth: preterm birth with intact membranes, 
PPROM, and indicated preterm birth (also known as provider initiated). Chen et al. 
analyzed a data set of 3 million births. They found that there was a higher risk of neonatal 
mortality in patients born after 28 weeks gestation with PPROM and indicated preterm 
birth as compared to those with preterm labor and intact membranes (Chen, Feresu, & 
Barsoom, 2009). In another large scale US data cohort, Kamath-Rayne et al. found 
similarly higher risk of post-neonatal (age 29-364 days) mortality for PPROM and 
indicated preterm births (Kamath-Rayne, DeFranco, & Chen, 2013). Further work by 
Delorme et al. refined these “causes” of preterm birth into more granular disease specific 
causes such as placental abruption, hypertensive disorder with or without fetal growth 
restriction, and fetal growth restriction without hypertensive disorder (Delorme et al., 
2016). To test for the risk of in-hospital mortality and to compare these groups, a model 
was built that included possible confounding prognostic factors. Statistical analysis 
showed that fetal growth restriction with or without hypertension was associated with a 
higher risk of neonatal death (3.0 and 2.3 adjusted odds ratios, respectively) (Delorme et 
al., 2016). 
In terms of morbidity, infants born preterm are at a greater risk of several short- 
and long-term complications. In fact, several studies have shown that as the survival rate 
of extremely preterm neonates has increased, so too has the incidence of many acute and 
chronic morbidities (Glass et al., 2015). In the aforementioned study by Manuck et al, the 
prevalence of major morbidities (intraventricular hemorrhage grade III/IV, seizure, 
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hypoxic ischemic encephalopathy, necrotizing enterocolitis stage II/III, 
bronchopulmonary dysplasia, or persistent pulmonary hypertension) and minor 
morbidities (hypotension, intraventricular hemorrhage grade I/II, necrotizing enterocolitis 
stage I, respiratory distress syndrome, and/or hyperbilirubinemia requiring treatment) 
differed based on gestational age (Manuck et al., 2016). Analysis showed that extremely 
preterm infants had high rates of major morbidities which decreased with each 
subsequent weak of gestation, while minor morbidities gradually increased and ultimately 
peaked at 81.7% prevalence around 31 weeks’ gestation (Figure 2). 
	
 
Figure 2: Major and minor morbidity prevalence by gestational age. Major 
morbidities include: intraventricular hemorrhage grade III/IV, seizures, hypoxic 
ischemic encephalopathy, necrotizing enterocolitis stage II/III, bronchopulmonary 
dysplasia, or persistent pulmonary hypertension. Minor morbidities include: 
hypotension, intraventricular hemorrhage grade I/II, necrotizing enterocolitis stage 
I, respiratory distress syndrome, and/or hyperbilirubinemia requiring treatment. 
Figure based on data from Manuck et al., 2016 
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Several longer-term chronic morbidities associated with prematurity include 
increased risk of cerebral palsy, neurodevelopmental abnormalities, cognitive 
developmental delay, hearing impairment, severe visual impairment (retinopathy of 
prematurity), and chronic lung disease (Glass et al., 2015). 
 
Improvements in Neonatal Care 
Over the last forty to fifty years, the advancement in neonatal and maternal 
treatment has dramatically decreased mortality and morbidity, and has improved 
outcomes, especially in preterm patients (Glass et al., 2015). The development of 
neonatal intensive care units, maternal-neonatal transport systems, and the increased use 
of antenatal corticosteroids for fetal lung maturation, tocolytic drugs to delay delivery, or 
magnesium sulfate for neuroprotection have all been paramount (Manuck et al., 2016; 
McIntire & Leveno, 2008). The use of exogenous surfactant led to reductions in mortality 
risk and became pivotal in the management of neonates suffering from respiratory 
distress syndrome (Suresh & Soll, 2003). Furthermore, studies investigating chronic lung 
disease in premature patients has led to the understanding of the harmful effects of 
postnatal steroids (Glass et al., 2015). While early results showed that postnatal steroids 
improved chronic lung disease outcomes and facilitated extubation following, steroid 
usage came at the expense of several adverse effects including but not limited to 
hyperglycemia, hypertension, and gastrointestinal bleeding (Halliday, 2017). 
One specific field of medicine which has contributed a great deal to improved 
neonatal outcomes is anesthesiology. Preterm newborns are especially vulnerable during 
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anesthesia due to their immature organ system growth (McCann & Soriano, 2014). The 
development of breathing circuits, artificial airways, and the Apgar score to assess 
breathing and identify the need for resuscitation efforts are just a few of these 
advancements (Glass et al., 2015). Additionally, the shift from endotracheal intubation 
and mechanical ventilation to continuous positive airway pressure (CPAP) allowed 
patients to continue spontaneous breathing without the need for intubation and, thereby, 
reduced the risk of lung damage from mechanical ventilation (Roberts, Badgery-Parker, 
Algert, Bowen, & Nassar, 2011). 
In terms of surgical innovation, there has been a rapid growth in minimally 
invasive surgery in neonates as a way to make smaller incisions, speed up postoperative 
healing, and lessen postoperative pain (McCann & Soriano, 2014). The miniaturization of 
common surgical tools has made laparoscopic and thoracoscopic surgical procedures 
much more feasible for common surgical procedures such as Nissen fundoplication, 
pyloromyotomy, and patent ductus arteriosus occlusions (Rothenberg, Chang, & Bealer, 
2004). 
 
Mortality Risk Assessment Tools 
 When caring for extremely sick preterm neonates, clinicians and parents are faced 
with countless difficult medical decisions. As a way to help medical teams make such 
complex decisions, various predictive risk assessment tools based on several prognostic 
factors have been developed over the years in an effort to quantify mortality risk and 
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illness severity (Figure 3). The following is a summary of current assessment tools and 
their use-cases. 
 The Clinical Risk Index for Babies (CRIB) was first developed in 1993, and was 
based on a cohort of 812 infants weighing less than 1500 grams and born less than 31 
weeks’ gestation across several UK hospitals (“The CRIB (clinical risk index for babies) 
score,” 1993). Statistical modeling was based on six prognostic factors assessed within 
the first 12 hours of life (birth weight, gestation, congenital malformation, base deficit, 
and minimum/maximum FiO2) to predict mortality (“The CRIB (clinical risk index for 
babies) score,” 1993). One of the main benefits of CRIB is the fact that it can be quickly 
and easily calculated as compared to other more complex assessment tools (Dorling, 
Field, & Manktelow, 2005).  
 In the United States in 1993, Richardson et al. published a similar mortality risk 
assessment scoring system, called the Score for Neonatal Acute Physiology (SNAP), 
based on a cohort of low birth weight patients from three Boston area hospitals 
(Richardson, Gray, McCormick, Workman, & Goldmann, 1993). The SNAP score is 
similar to CRIB but differs in several key ways. First, SNAP’s model design and 
framework was based on current adult and pediatric mortality risk assessment tools, the 
Acute Physiology and Chronic Health Evaluation (APACHE) and the Physiological 
Strain Index (PSI) respectively (Richardson, Gray, et al., 1993). Second, SNAP includes 
many more prognostic factors (28 in total) which are measures of organ physiology 
derangement during the first 24 hours of life (Richardson, Gray, et al., 1993). Lastly, 
during the model design process these 28 prognostic factors were weighted by expert 
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opinion as opposed to the statistical modeling used in CRIB (Dorling et al., 2005). As a 
way to correlate the SNAP illness severity score to mortality, Richardson et al. expanded 
on their work to produce the SNAP-Perinatal Extension (SNAP-PE) which, in 
conjunction with birth weight and SNAP score, was able to estimate neonatal mortality 
(Richardson, Phibbs, et al., 1993).  
 While the SNAP and CRIB assessment scores both became widely validated and 
their use became more prevalent in neonatal intensive care units, they were not without 
their faults. In the early 2000s, second-generation assessment scoring systems brought 
about several key and important changes to both SNAP and CRIB. 
 The SNAP-II was first published by Richardson et al. in 2001, promising a 
simplified scoring system based on an updated cohort of patients (Richardson, Corcoran, 
Escobar, & Lee, 2001). While the original SNAP score requires 28 prognostic factors, the 
new SNAP-II requires only 6 (mean blood pressure, lowest temperature, PO2/FiO2 ratio, 
lowest serum pH, multiple seizures, and urine output). Additionally, a big change to 
SNAP-II was that data from patients was only collected within the first 12 hours of life, 
as compared to 24 hours in the original SNAP score, in an effort to eliminate treatment 
bias (Richardson et al., 2001). While the original SNAP score utilized clinical weighting 
for its prognostic factors, the SNAP-II score introduced statistical modeling to help 
Richardson et al. eliminate factors that were not correlated with mortality or were 
redundant (Richardson et al., 2001). Just as with SNAP, the SNAP-II was extended to 
produce the SNAPPE-II, which gives clinicians a predicative mortality risk assessment 
(Dorling et al., 2005). 
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In 2003 the CRIB II was introduced as an updated assessment tool for 
determining neonatal mortality risk. The new score eliminated prognostic factors such as 
FiO2 and introduced new variables such as sex and temperature at admission (Parry, 
Tucker, Tarnow-Mordi, & UK Neonatal Staffing Study Collaborative Group, 2003). 
Because FiO2 is not a true physiological measurement, and its value is determined by the 
medical care team, Parry et al. chose to remove this variable to reduce the risk of 
treatment bias. By removing FiO2, adding additional variables, and validating the model 
with a more recent cohort of patients, the score was intended to give improved results as 
compared to the original CRIB score. (Parry et al., 2003). 
While these second-generation systems offer simplified scoring, making it easier 
to use in clinical practice, and were validated on an updated cohort of patients, they are 
not without limitations. With both CRIB II and SNAPPE-II, since all prognostic factors 
are taken within the first 12 hours of life, they have limited effectiveness for assessing 
mortality risk later in life. In addition, these scoring systems fail to include any 
information on potential surgical interventions a patient might have had. For these 
reasons, and more that will be expanded on later, the current set of standard illness 
severity scoring systems and mortality risk assessments tools are not applicable to all 
cohorts of patients, and there exists an opportunity to develop a novel scoring system 
more suited towards a high-risk cohort of preterm neonatal patients who undergo a 
surgical procedure.  
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Table 3: Prognostic Factors Used in Several Popular Illness Severity Scoring 
Systems 
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SPECIFIC AIMS 
 
 The specific aim of this study is to compare various patient demographic and 
clinical characteristic variables between deceased and surviving preterm neonates who 
had at least one surgical procedure at Boston Children’s Hospital within the first 30 days 
of life. Using a combination of descriptive and inferential statistics, we hope to identify 
trends in mortality and/or morbidity for this patient population of preterm neonates. We 
hope to use these results to develop a multivariable logistic regression model to better 
predict mortality risk depending on the severity and number of different demographic and 
clinical characteristics identified in the study. While current mortality risk assessment 
tools exist, none are applicable to this cohort of preterm surgical neonates. In addition,, 
there have been substantial advancements in medical technology and provider education 
that necessitate the need for new mortality risk assessment tools. By creating a new 
predictive mortality risk model more suited towards this cohort of patients, this 
assessment tool could be used in the future to help assist clinicians and families make 
complex medical decisions about necessary or justifiable potential medical treatment 
options.  
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METHODS 
 
 After IRB approval, medical records were obtained from Boston Children’s 
Hospital (BCH) electronic medical record, PowerChart, for patients matching the 
following criteria: 
 
• Date of birth ranging from 2015 to 2018 
• Gestational age at birth less than 39 weeks 
• Had at least one surgical procedure at BCH within the first 30 days of life 
 
Patient demographic information in addition to lab values and clinical information in 
regards to the surgical procedure was obtained (Table 4). All data was pulled from 
patient’s electronic medical records at BCH by IT staff in the Department of 
Anesthesiology, Critical Care and Pain Medicine, with the exception of “Number of 
Cardiopulmonary Resuscitation (CPR) Attempts” and “End of Life Care Redirected”, 
which was obtained via manual chart review by research staff. For clinical lab values 
such as pH, pO2, pCO2 and base excess, these values were taken from patient records 24 
hours prior to surgery. In addition, patients’ medication use while at BCH was pulled 
from electronic medical records (see Appendix for complete medication lists). 
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Table 4: Research Variables of Interest 
 
Patient Demographics 
Gender 
Weight 
Gestational Age 
Clinical Variables 
Procedure Type 
Cardiac/Non-Cardiac 
ASA Status 
1 to 5 
Lactate Values 
Number of CPR Attempts 
End of Life Care Redirected? (Y/N) 
Age of Death 
Acid Base Disorder: 
pH, pO2, pCO2, base excess, bicarbonate 
Airway Assessment: 
Ventilator Use (Y/N) 
Blood Products 
Medication Usage: 
Bronchodilators 
Emergency Resuscitation 
Vasopressors/Inotropic Agents 
 
 “Medication usage” will be assessed by detailing if a patient got a medication 
from one of four categories based on the “Emergency Drug Dose Recommendation” 
guidelines of BCH (Boston Children’s Hospital, 2016). At the time of writing, acid base 
disorder, airway assessment, and medication usage data are not available as these data are 
still in the process of being retrieved from patient records by BCH IT staff. Additionally, 
patients’ gestational age was categorized based on previous, known guidelines from the 
WHO and American Academy of Pediatrics (AAP) (Table 5) (“Preterm birth,” 2018; 
Schonhaut et al., 2015).  
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Table 5: Gestational Age Categories 
 
Category Gestational Age (weeks) 
Extremely Preterm < 28 Weeks 
Very Preterm 28 Weeks 0 Days to 31 Weeks 6/7 Days 
Moderate Preterm 32 Weeks 0 Days to 33 Weeks 6/7 Days 
Late Preterm 34 Weeks 0 Days to 36 Weeks 6/7 Days 
Early Term 37 Weeks 0 Days to 38 Weeks 6/7 Days 
 
 A univariate analysis of patient demographics was done between deceased and 
surviving patient groups. For the clinical variables of interest, a set of descriptive 
statistics was performed, as data from the surviving group were not available.  
 
Statistical Analysis 
  Due to the non-normality of the sample and the relatively small sample size, the 
Wilcoxon rank sum test was used as opposed to the Student’s t-test for comparing two 
independent groups of continuous variables. The non-parametric Wilcoxon rank sum test 
provides a more conservative estimate in this regard. In addition, descriptive statistics 
such as medians and interquartile ranges were calculated and presented for all continuous 
variables. 
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 When analyzing the categorical variables of the data set, Fischer’s exact test was 
used to assess the distribution of the categorical variables between the deceased and 
surviving patient groups. Due to the relatively small sample size in certain categories of 
certain variables, the more conservative non-parametric Fischer’s exact test was chosen 
instead of a Chi square test, which relies on making distribution assumptions with regard 
to the specific categories of a categorical variable.   
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RESULTS 
 
 A total of 653 patients were included in the dataset, 56 of whom were deceased, 
an overall 8.6% mortality rate. Median gestational age of the deceased and surviving 
patient groups was 35 and 36 weeks respectively (p=0.076). In the deceased patient 
group, 64% of patients were male, 36% female.  In the surviving group 54% of the 
survivors were male, 46% female. (p=0.234). 
 Mortality rates were statistically different across gestational age categories 
(p=0.015), and there were significant differences in mortality rate based on ASA 
classification (p<0.001) between deceased and surviving patient groups. Patient weight 
was also found to be statistically different between deceased and surviving patient groups 
(p=0.009). 
 Of the 56 patients in the deceased group, 62.5% of the surgical procedures were 
cardiac related cases. (Data for surgeries for the surviving group is not yet available.) The 
median age of death for patients in the deceased group was 46 days (interquartile range 
25-109) and the median lactate value for the deceased patient group was 6.5 mmol/L 
(interquartile range 4.3-8.7). At the time of writing, data from surviving patients on these 
variables and the clinical variables that follow are not yet available. In addition, 60% of 
the patients in the deceased group had one surgical procedure and 51.8% had no CPR 
attempts. Lastly, 58.9% of patients in the deceased group had their care ultimately 
redirected to comfort measures only. 
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Table 6: A Comparison of Patient Characteristics and Demographics Between 
Deceased and Surviving Patients 
Characteristic Deceased Survivors P 
N 56 597  
Gestational Age (weeks) 35 (33, 38) [24, 38] 
36 (34, 38) 
[24, 38] 0.076 
Extremely Preterm  
<28 Weeks 9 (16.1%) 84 (14.1%) 
  0.015*2 
Very Preterm 
28 Weeks 0 Days to 31 Weeks 6/7 
Days 
4 (7.1%) 24 (4.0%) 
Moderate Preterm 
32 Weeks 0 Days to 33 Weeks 6/7 
Days 
10 (17.9%) 36 (6.0%) 
Late Preterm 
34 Weeks 0 Days to 36 Weeks 6/7 
Days 
12 (21.4%) 173 (29.0%) 
Early Term 
37 Weeks 0 Days to 38 Weeks 6/7 
Days 
21 (37.5%) 280 (46.9%) 
Weight (kg) 2.2 (1.5, 2.9) [0.7, 3.8] 
2.6 (1.9, 3.2) 
[0.6, 4.5]   0.009* 
ASA    
I 0 (0%) 11 (1.8%) 
<0.001* 
II 0 (0%) 73 (12.2%) 
III 7 (12.5%) 206 (34.5%) 
IV 44 (78.6%) 299 (50.1%) 
V 5 (8.9%) 7 (1.2%) 
Gender    
Female 20 (35.7%) 272 (45.6%) 
0.234 
Male 36 (64.3%) 324 (54.4%) 
Values are presented as n (%) for categorical data or median (IQR) [range] for continuous data. 
P values comparing survivors and deceased patients are computed using the Wilcoxon rank 
sum test or Fisher's exact test as appropriate. 
*Statistically significant. 
																																																								2	The	p-value	for	this	test	is	comparing	mortality	rates	by	gestational	age	to	assess	if	any	differences	in	mortality	rates	exist	between	gestational	age	categories	
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Table 7: Descriptive Statistics of the Deceased Group  
Characteristic Frequency  
Procedure Type   
Cardiac 35 (62.5%)  
Non-Cardiac 21 (37.5%)  
Age of Death (days) 46 (25, 109) [1, 1342]  
Lactate (mmol/L) 6.5 (4.3, 8.7) [1.3, 15] 
 
End of Life Care Redirected 33 (58.9%)  
Number of procedures   
1 33 (60%)  
2 14 (25.5%)  
3 5 (9%)  
4 3 (5.5%)  
Number of CPR Events   
0 29 (51.8%)  
1 16 (28.6%)  
2 10 (17.9%)  
3 0 (0%)  
4 0 (0%)  
5 1 (1.8%)   
Values are presented as n (%) for categorical data or median (IQR) [range] for continuous data. 
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DISCUSSION 
 
 The significance and impact of prematurity is a worldwide phenomenon with 
pervasive effects, even in developed countries like the United States (World Health 
Organization et al., 2012). With advances in neonatal care, minimally invasive surgery, 
and anesthesia of the neonatal patient, there have been decreases in neonatal mortality 
and morbidity over the past twenty years (Glass et al., 2015). However, even with today’s 
advances in medical knowledge, technology, and provider training, preterm neonates still 
remain an incredibly fragile and at-risk patient population. The use and prevalence of 
illness severity scoring systems and mortality risk assessment tools at NICUs around the 
country provide added information to clinicians and medical teams faced with countless 
complex medical decisions (Dorling et al., 2005). The two most popular mortality risk 
assessment systems, CRIB II and SNAPPE-II, were first developed and validated based 
on cohorts of patients from the late 1990s and have been since independently validated on 
cohorts of patients from the mid 2000s (Reid, Bajuk, Lui, Sullivan, & NSW and ACT 
Neonatal Intensive Care Units Audit Group, PSN, 2015). However, these assessment 
tools have limited application to our cohort of patients, chiefly because they fail to 
consider inherent surgical risk amongst other limitations. While it is important to realize 
that no one score can capture the prognosis and mortality risk of a neonate, there are 
certainly specific areas where improvements can be made to better predict mortality risk 
in today’s preterm neonate. 
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 One area of improvement is to develop a mortality risk assessment model based 
on an entirely new cohort of patients from more recent data. While there have been some 
validation studies of CRIB II and SNAPPE-II on more recent patient populations, the 
cohorts used in these recent validation studies have not been representative of the patient 
population at BCH (Reid et al., 2015). More specifically, both CRIB II and SNAPPE-II 
failed to factor in any prognostic factors that might be associated with mortality for 
patients undergoing surgery, a requisite criterion for inclusion in this study. Moreover, 
while SNAPPE-II and CRIB II have seen validation in newer cohorts of patients, the 
original model design was done on cohorts of patients from the 1990s. This means 
possible prognostic factors might have been eliminated in the original model design by 
Richardson et al. and Parry et al., respectively, due to the lack of significant association 
with mortality because of limited knowledge and a different prognostic assessment of 
neonatal patient outcomes by clinicians at the time. Another important limiting factor in 
the usefulness of SNAPPE-II and CRIB II is the fact that both use prognostic factors 
taken from patients within the first 12 hours of life.  This could affect the accuracy and 
effectiveness of SNAPPE-II and CRIB II to estimate neonatal mortality (Dorling et al., 
2005). In the deceased group of this study the median age of death is 46 days. Therefore, 
the lack of data past 12 hours might limit the accuracy of SNAPPE-II and CRIB II to 
predict mortality in this cohort.   
 While the model design process has not yet begun, the current set of results 
provides some interesting talking points and consideration of possible prognostic factors 
to include in a future predictive risk assessment model. The first point to note is that 
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mortality occurs at a high rate. The mortality rate of our cohort is 8.6%, which is 
considerably higher than the United States preterm mortality rate of 1.4% from 2016 
(Manuck et al., 2016). The results of this study also show several prognostic factors that 
have significant associations with mortality. Mortality rate  varied significantly  with 
gestational age  (p=0.015), a finding that is consistent with past literature by Manuck et 
al. (Manuck, 2017). Results also showed significantly different mortality rates based on 
birth weight (p=0.009), as with past studies (Ray et al., 2017). The last prognostic factor 
that had a significant effect on mortality rate between deceased and surviving patients 
was ASA classification (p<0.001), which is a physical classification system used to 
categorize patients by physiological status and can be helpful for determining operative 
risk (Doyle & Garmon, 2018). These results are expected, as one might assume patients 
with a more compromised physiological state would carry a greater risk of mortality 
intraoperatively and postoperatively. No other illness severity score or mortality risk 
assessment tool to our knowledge has included ASA classification as a risk factor in 
developing a model in the neonate population. One interesting area of note is that these 
results showed no statistically significant difference in mortality rate based on gender 
(p=0.234), unlike several past studies describing a higher mortality risk for males as 
compared to females (Ray et al., 2017). One possible explanation for the lack of 
significance is the limited number of patients in the deceased group. While the deceased 
group had a greater proportion of males to females as compared to the surviving group 
(64.3% versus 54.4% respectively) the sample size of 56 patients in the deceased group 
limited the statistical significance of this finding.  
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 Descriptive statistics of clinical variables were performed in the deceased group. 
At the time of writing, however, comparable data from our surviving group was not 
available. Therefore, no statistical comparisons could be performed to determine if there 
were any significant associations with mortality. A clinical variable that one might expect 
to be associated with mortality risk is lactate levels. Lactate is a common lab value that 
can be used as a prognostic indicator for total illness severity, and, in fact, the median 
lactate value 24 hours prior to surgery in the deceased cohort is 6.5 mmol/L, which is 
considered a high value (>4 mmol/L) (Andersen et al., 2013). In addition, nearly half 
(48.2%) of patients in the deceased group had at least one CPR event, and roughly 40% 
had more than one procedure, both possible prognostic factors for mortality based on the 
increased physiological stress and compromised health of neonates requiring multiple 
interventions to sustain life. 
 Ongoing research for this study has been focused on three specific areas of 
analysis prior to developing a statistical model: pre-operative ventilation, patient 
medications, and acid-base disorders. It is known that preterm neonates are born with 
immature organ systems, especially a compromised respiratory system (Roberts et al., 
2011). While advances in care such as antenatal corticosteroids and postnatal surfactant 
have improved outcomes, the need for mechanical ventilation to sustain life prior to 
surgery was estimated to be a significant prognostic factor when building a neonatal 
mortality risk model (Glass et al., 2015). While many different types and modes of 
mechanical ventilation exist, it was difficult to ascertain these specifics with enough 
clarity given the data on hand from patient records. For that reason, future analysis on 
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mechanical ventilation will be limited to whether or not a patient was on any type of 
mechanical ventilation 24 hours prior to their surgical procedure. 
 The second current area of analysis is identifying and categorizing patient blood 
products and medications that could possibly be associated with mortality risk (see 
Appendix for full list of medications). Four specific categories of treatments from BCH’s 
“Emergency Drug Dose Recommendation” guidelines were chosen to be investigated to 
determine if there was any association with neonatal mortality: blood products, 
bronchodilators, emergency resuscitation, and vasopressors/inotropic agents (Figure 4) 
(Boston Children’s Hospital, 2016).  
 
Table 8: Emergency Drug Dose Recommendation guidelines taken from Boston 
Children’s Hospital, 2016 
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Lastly, work is being done to analyze this cohort of patients for potential acid-
base disorders, given their arterial pH, pO2, pCO2, base deficit, and bicarbonate 
concentration 24 hours prior to surgery. Signs of metabolic acidosis can be the result of 
neonatal asphyxia (due to impaired blood gas exchange) leading to brain damage, 
encephalopathy and respiratory complications (Low, Lindsay, & Derrick, 1997).  
Unfortunately, at the time of writing, patient data on ventilation status, medication 
usage, and acid base disorders is not yet available. BCH IT data analysts are still in the 
process of retrieving this information from PowerChart patient records, and the level of 
completeness for all patients in the cohort is unknown. For this reason, the statistical 
model design portion of the study has not yet begun, as current work is focused on 
finishing the complete list of potential prognostic factors of neonatal mortality to include 
in the future model. Although a statistical mortality risk model has not yet been 
developed, it is important to understand how to develop such a model, what important 
factors to consider when building a model, and ways to test a model’s performance and 
validity for robustness. 
 Logistical regression is a common analysis tool used to create a statistical model 
to calculate mortality risk, and has been used in SNAPPE-II, CRIB II, and other mortality 
risk assessment studies (Dorling et al., 2005). By incorporating the strongest predictors of 
mortality, logistic regression allows one to generate a direct probability model, with no 
assumptions about the variables, on a specific binary outcome (mortality in this case) 
(Harre, Lee, & Pollock, 1988). To identify the strongest predictors of mortality, 
univariate analysis of possible prognostic factors is done. While several significant 
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prognostic patient characteristics and demographics have been identified in this cohort, 
further univariate analysis needs to be performed on future ventilation use and medication 
category data to identify any predictive effect on mortality. Afterwards, a multivariable 
logistic regression can be generated using a statistical software package (e.g. STATA) to 
calculate the beta coefficients of each covariate and identify the 3 to 4 strongest 
independent predictors of mortality. Using this model, one can calculate a predictive 
probability of mortality for each unique covariate pattern of prognostic factors (Harre et 
al., 1988). The next step after creating a logistic regression model and predictive risk 
algorithm is to assess its performance and validation. 
 There are several key performance measures that are commonly analyzed in 
mortality risk assessment models: accuracy, calibration, and discrimination (Medlock, 
Ravelli, Tamminga, Mol, & Abu-Hanna, 2011). Firstly, accuracy is a measure of the 
effectiveness to correctly predict an actual outcome (Dorling et al., 2005). In a systematic 
review of 41 developmental studies, Medlock, et al. found that the most common ways 
that accuracy was assessed were: negative predictive value, positive predictive value, 
specificity and sensitivity (Medlock et al., 2011). Second, calibration is a measure of how 
a model’s predictive probability can accurately assess the actual probability, and it is 
commonly assessed using the Hosmer-Lemeshow goodness of fit test (Medlock et al., 
2011). Lastly, discrimination refers to the ability of a model to accurately differentiate 
patients with the same outcomes, and it is frequently measured using the area under the 
receiver operator curve (AUC) (Dorling et al., 2005). All of these performance measures 
can be calculated using a statistical software package, and they are commonly used in 
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literature as a basis of comparison to determine which model does a better job at 
predicating mortality (Dorling et al., 2005; Reid et al., 2015). 
 After testing the performance of any future predictive mortality risk model, the 
next step would be to validate the model. Validation would most likely be done on a 
cohort of patients from a comparable children’s hospital with similar resources, provider 
training, and high-risk patient population to BCH as a way to see how well the model 
accurately predicts mortality in a new dataset. Importantly, validating the model on a 
prospective (as opposed to retrospective) cohort of patient would further add to the 
robustness of the model to accurately predict future outcomes (Dorling et al., 2005). 
Validating the model on several cohorts of prospective neonates would also show the 
reproducibility of the model to assess consistent and accurate mortality risk on new 
groups of unique patients.   
While the conclusions of this study are still far off, the data collected so far 
provide a good opportunity to look at the project critically and to assess the current 
limitations and areas of improvement for future work. A total of 653 patients met the 
inclusion criteria for this study, which presents a possible limitation to the robustness of 
our model design, especially when considering that the base cohorts used in the design of 
SNAPPE-II and CRIB II had several thousand patients from multiple clinical sites (Parry 
et al., 2003; Richardson et al., 2001). Improvements in the future could easily be made by 
expanding the data set to a larger time period (currently only patients born from 2015 to 
2018 were investigated) and also including patients from multiple clinical sites to get a 
more representative patient cohort. Other areas of improvement include expanding the 
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scope of clinical lab values analyzed, beyond just lactate. While lactate data was used as 
a representative of total illness severity, a similar study examining prognostic factors of 
surgical neonates by Manchada et al. examined additional lab values such as: white blood 
cell count, platelets, and c-reactive protein (Manchanda, Sarin, & Ramji, 2012). Looking 
at c-reactive protein in particular is likely to be a useful data point, given the fact that it is 
commonly used as a sign of infection, sepsis, septic shock, and organ dysfunction 
(Castelli et al., 2004). Other variables to consider, that were not included in this analysis, 
are urine output and creatinine levels. Both elevated levels of creatinine and decreased 
urine output are known prognostic factors for neonatal renal failure (Chevalier, 
Campbell, & Brenbridge, 1984). To assess for neurological derangement, future studies 
could add information from either the pediatric Glasgow Coma Scale (PGCS) or the 
Infant Comas Scale (ICS), both of which have shown to be good assessments of pediatric 
mental status (Ahn, Sohn, & Lee, 2010; Jain & Iverson, 2018). Another alternative for 
assessing neurologic injury is the CHOP Infant Coma Scale, or Infant Face Scale (IFS), 
which was shown to be good reliable index for brain injury severity and 
hypoxemia/ischemia in a 2000 study by Durham et al. (Durham et al., 2000). Lastly, one 
potential area for improvement would be to add Apgar scores at 5 minutes to the analysis. 
SNAPPE-II includes 5 minute Apgar scores in its assessment criteria, and several past 
studies have shown Apgar at 5 minutes to be strongly associated with neonatal and infant 
death (Iliodromiti, Mackay, Smith, Pell, & Nelson, 2014). 
In conclusion, while several current neonatal mortality risk and illness severity 
scoring systems currently exist, there are several key ways in which these can be updated 
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with modern standards to be more representative in today’s current medical landscape 
and more applicable to a cohort of preterm neonates undergoing surgery. The main 
failure of these scoring systems is the reliance on data solely from the first 12 hours of 
life and the lack of data for a surgical cohort, severely limiting its potential effectiveness 
in a patient population such as that at BCH. Analyzing a cohort of 653 patients has 
identified several key demographic and patient characteristics that are associated with 
mortality: gestational age, weight, and ASA classification. While preliminary work has 
begun on evaluating many of the clinical variables of interest, more analyses are required 
to understand the significance of these variables and all the factors as a whole, and to 
start the processes of building a logistic regression model and validating its performance 
and reliability to assess mortality risk.   
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APPENDIX 
 
Table 9: A Complete List of Medications in the Methods Discovery
1/2 Normal Saline 500 mL 
Acetaminophen mg IV 
Acetaminophen mg PO 
Acetaminophen mg PR 
Acyclovir (Zovirax) mg 
Adenosine mg 
Adenosine mg IV 
Albumin 5% mL 
Albuterol- Nebulizer mL Inhalation 
Albuterol- Puff (90 mcg per puff) puff Circuit 
Albuterol- Puff (90 mcg per puff) puff Inhalation 
Albuterol- Puff (90 mcg per puff) puff Nebulizer 
Aminocaproic Acid mg 
Aminocaproic Acid mg IV 
Amiodarone mg 
Ampicillin mg IV 
Antithrombin III units 
Atropine mg 
Atropine mg IM 
Atropine mg IV 
Autologous Blood mL 
Basiliximab (Simulect) mg 
Bumetanide mg 
Bupivacaine 0.1% mL 
Bupivacaine 0.125% + epi 1/200k mL Caudal 
Bupivacaine 0.125% mL 
Bupivacaine 0.125% mL Caudal 
Bupivacaine 0.125% mL Epidural 
Bupivacaine 0.125% mL Peripheral Nerve Block 
Bupivacaine 0.25% mL Caudal 
Bupivacaine 0.25% mL Epidural 
Bupivacaine 0.25% mL Peripheral Nerve Block 
Bupivacaine 0.5% Isobaric mL Intrathecal 
Bupivacaine 0.75% D8.25 mL Intrathecal 
Calcium Chloride mg IV 
Calcium Gluconate mg 
Calcium Gluconate mg Circuit 
Calcium Gluconate mg Intrathecal 
Calcium Gluconate mg IV 
Cefazolin mg Circuit 
Cefazolin mg IV 
Cefepime mg 
Cefotaxime mg IV 
Cefoxitin mg IV 
Cell Saver Washed PRBC mL 
Cell Saver mL 
Chloroprocaine 1.5% mL 
Chloroprocaine 1.5% mL Caudal 
Chloroprocaine 1.5% mL Epidural 
Chloroprocaine 3% mL 
Chloroprocaine 3% mL Caudal 
Chloroprocaine 3% mL Epidural 
Cisatracurium mg 
Cisatracurium mg IV 
Clindamycin mg 
Clindamycin mg IV 
Clonidine mcg 
Clonidine mcg Caudal 
Concentrated Platelets mL 
Cryoprecipitate mL 
Crystalloid mL 
D10 1/2 Normal Saline mL 
D10 Normal Saline mL 
D25 mL 
D5- Sodium Bicarbonate mL 
D5 1/2 Normal Saline mL 
D5 1/4 Normal Saline mL 
D5 Lactated Ringers 500 mL mL 
D5 Lactated Ringers mL 
D5 Normal Saline mL 
D50 mL 
D5W 1/2 Normal Saline mL 
Dexamethasone mg IV 
Dexmedetomidine mcg 
Dexmedetomidine mcg IV 
Dextrose (g) g IV 
Dextrose 10% Water mL 
Dextrose 5% Water mL 
Dopamine mcg 
Ephedrine mg IV 
Epinephrine mcg 
Epinephrine mcg Intrathecal 
Esmolol mg 
Esmolol mg IV 
Etomidate mg IV 
Factor VIIa mg 
Factor VIII (Human) IU 
Factor VIII IU 
Fenoldopam mcg 
Fentanyl mcg 
Fentanyl mcg Circuit 
Fentanyl mcg IM 
Fentanyl mcg IV 
Fluconazole (Diflucan) mg 
Fresh Frozen Plasma mL 
Furosemide mg 
Furosemide mg Circuit 
Furosemide mg IV 
Gentamicin mg 
Glycopyrrolate mg IV 
Heparin units 
Heparin units Circuit 
Heparin units IV 
Hydralazine mg 
Hydralazine mg IV 
Hydrocortisone mg IV 
Hydromorphone mg IV 
ICU Fluid- See CHAMPS for Details mL 
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Insulin units 
Insulin units IV 
Intralipid 20% mL 
Isoflurane % Inhalation 
Isoproterenol mcg 
Ketamine mg 
Ketamine mg IV 
Labetalol mg IV 
Lactated Ringers mL 
Lidocaine 1% + epi 1/200k mL Caudal 
Lidocaine 1% mL Epidural 
Lidocaine 1% mL Inhalation 
Lidocaine 1% mL IV 
Lidocaine 1% mL Topical 
Lidocaine 1.5% with epi 1/200k (Test Dose) mL Epidural 
Lidocaine 2% + epi 1/200k mL Caudal 
Lidocaine 2% Jelly Application Topical 
Lidocaine 2% mL Topical 
Lidocaine mg 
Lidocaine mg IV 
Lidocaine mg Topical 
Lipids mL 
Magnesium Sulfate mg IV 
Mannitol g Circuit 
Meropenem mg IV 
Methylprednisolone mg Circuit 
Methylprednisolone mg IV 
Midazolam mg 
Midazolam mg Circuit 
Midazolam mg IV 
Milrinone mcg 
Milrinone mcg IV 
Morphine mg 
Morphine mg IV 
Neostigmine mg IV 
New Fluid mL 
New Medication- mg Infusion mg 
New Medication- mg mg IV 
New Medication- mL Infusion mL 
Nicardipine mcg 
Nitric Oxide ppm Circuit 
Nitric Oxide ppm Inhalation 
Nitroglycerin mcg 
Nitroglycerin mcg IV 
Nitroprusside mcg 
Nitroprusside mcg Circuit 
Norepinephrine mcg 
Norepinephrine mcg IV 
Normal Saline mL 
Octreotide mcg 
Ondansetron mg IV 
Oxacillin mg 
Packed Red Blood Cells mL 
Pancuronium mg IV 
Pantoprazole mg IV 
Parenteral Nutrition mL 
Phentolamine mg Circuit 
Phenylephrine mcg 
Phenylephrine mcg Circuit 
Phenylephrine mcg IV 
Piperacillin/Tazobactam(Zosyn) mg 
Piperacillin/Tazobactam(Zosyn) mg Circuit 
Piperacillin/Tazobactam(Zosyn) mg IV 
Plasma-Lyte mL 
Platelets mL 
Potassium Chloride (KCI) mEq 
Potassium Chloride (KCI) mEq IV 
Procainamide mg 
Procainamide mg IV 
Propofol mg 
Propofol mg IV 
Prostaglandin E1 (Alprostadil) mcg 
Protamine mg IV 
Pump Blood mL 
Ranitidine mg IV 
Recovered Cardioplegia Circuit Volume mL 
Remifentanil mcg 
Remifentanil mcg IV 
Rocuronium mg 
Rocuronium mg Circuit 
Rocuronium mg IM 
Rocuronium mg IV 
Ropivacaine 0.1% mL 
Ropivacaine 0.1% mL Caudal 
Ropivacaine 0.1% mL Epidural 
Ropivacaine 0.1% mL Peripheral Nerve Block 
Ropivacaine 0.2% mL Caudal 
Ropivacaine 0.2% mL Epidural 
Ropivacaine 0.2% mL Peripheral Nerve Block 
Salvaged Red Cells mL 
Sodium Bicarbonate mEq 
Sodium Bicarbonate mEq Circuit 
Sodium Bicarbonate mEq IV 
Special Fluids- See CHAMPS for Details mL 
Succinylcholine mg IM 
Succinylcholine mg IV 
Sucrose mL PO 
Sufentanil mcg 
Sugammadex mg IV 
Tranexamic Acid mg 
Tranexamic Acid mg Circuit 
Tranexamic Acid mg IV 
Unasyn mg 
Unasyn mg IV 
Vancomycin mg 
Vancomycin mg IV 
Vasopressin units 
Vasopressin units IV 
Vecuronium mg 
Vecuronium mg Circuit 
Vecuronium mg IV 
Vitamin K  mg IM 
Vitamin K  mg IV 
Whole Blood mL 
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